UNSPSC 51393604: Indacaterol

This classification denotes a beta-adrenergic agonist with the molecular formula C24H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8OR09251MQ, chemically known as 5-{(1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one but generally known as indacaterol, which bears US NIH Compound Identifier 6433117. European Medicines Agency schedules Indacaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30138.

UNSPSC 51393604 Indacaterol is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged under it reflect a material mismatch: the Seminole County procurement seeks naloxone and drug deactivation systems, while the Texas Health and Human Services Commission RFI addresses direct-to-manufacturer prescription programs broadly. Neither solicitation involves indacaterol, an inhalant bronchodilator used in chronic obstructive pulmonary disease treatment. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope, and the tagged opportunities appear to reflect broader pharmacy procurement and opioid-response initiatives rather than indacaterol-specific demand.

State and local health departments and human services agencies are the primary issuing bodies appearing in the recent record. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and drug deactivation systems with quarterly deliveries and a July 26, 2023 response deadline (note: date inconsistency in source); the Texas HHS Commission issued an RFI on April 3, 2026, to explore direct-to-manufacturer prescription contracting models. Geographic activity centers on Florida and Texas based on these two records. Without additional opportunities specifically requesting indacaterol procurement, the code does not present a clear current market signal for vendors focused on that pharmaceutical line.